ARTICLE | Clinical News
IDN-6556: Started Phase I safety trial
January 2, 2001 8:00 AM UTC
Idun Pharmaceuticals Inc., La Jolla, Calif. Product: IDN-6556 Business: Metabolic Therapeutic category: Apoptosis Target: Caspase proteases Description: Small molecule broad spectrum caspase inhibitor...